Psychopharmacology

, Volume 231, Issue 1, pp 37–42

Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study

Original Investigation

Abstract

Rationale

Limited evidence from randomised controlled trials suggests that varenicline might be more effective than nicotine replacement therapy (NRT) in achieving abstinence from smoking. The comparative effectiveness of varenicline when prescribed under routine circumstances and in the general population has not been tested.

Objectives

To compare the abstinence rates of smokers trying to stop having used varenicline vs. NRT on prescription (Rx) when provided with minimal professional support in the general population while adjusting for key potential confounders.

Methods

A large survey of a representative sample of the English population. Participants were 1,579 adults who smoked within the previous 12 months and made at least one quit attempt with varenicline or NRT Rx in their most recent quit attempt. The main outcome measure was self-reported abstinence up to the time of the survey, adjusted for key potential confounders including urges to smoke. A sensitivity analysis was conducted in subsamples in which the quit attempt started up to 6 months or more than 6 months ago.

Results

The adjusted odds of abstinence in users of varenicline were 1.76 (95 % CI = 1.22–2.53) times higher compared with users of NRT Rx. However, there was no detectable difference in the subsample of smokers who started their quit attempt more than 6 months ago (adjusted OR = 1.03, 95 %CI = 0.54–1.96).

Conclusions

Varenicline use with minimal professional support in the general population of smokers appears more effective than NRT Rx in achieving short-term abstinence. However, this effect may disappear in the long-term. Research is needed to confirm this and establish what may underlie it.

Keywords

Smoking cessation Varenicline Nicotine replacement therapy on prescription Cross-sectional population survey 

References

  1. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Reeves KR (2008) Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 63(8):717–724. doi:10.1136/thx.2007.090647 PubMedCentralPubMedCrossRefGoogle Scholar
  2. Biazzo LL, Froshaug DB, Harwell TS, Beck HN, Haugland C, Campbell SL, Helgerson SD (2010) Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy. Nicotine Tob Res 12(6):567–573. doi:10.1093/ntr/ntq045 PubMedCrossRefGoogle Scholar
  3. Borland R, Partos TR, Cummings KM (2012) Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop smoking medications. Nicotine Tob Res 14(12):1483–1487. doi:10.1093/ntr/nts002 PubMedCrossRefGoogle Scholar
  4. Brose L, West R, Stapleton J (2013) Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc 88(3):226–233PubMedCrossRefGoogle Scholar
  5. Brose LS, West R, McDermott MS, Fidler JA, Croghan E, McEwen A (2011) What makes for an effective stop smoking service? Thorax. doi:10.1136/thoraxjnl-2011-200251 PubMedGoogle Scholar
  6. Dhelaria RK, Friderici J, Wu K, Gupta E, Khan C, Rothberg MB (2012) Effectiveness of varenicline for smoking cessation at two urban academic health centers. Eur J Intern Med 23(5):461–464PubMedCrossRefGoogle Scholar
  7. Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 328(7455):1519–1510PubMedCrossRefGoogle Scholar
  8. Fidler J, Shahab L, West O, Jarvis M, McEwen A, Stapleton J, West R (2011a) ‘The Smoking Toolkit Study’: a national study of smoking and smoking cessation in England. BMC Publ Health 11(1):479CrossRefGoogle Scholar
  9. Fidler JA, Shahab L, West R (2011b) Strength of urges to smoke as a measure of severity of cigarette dependence: comparison with the Fagerstrom test for nicotine dependence and its components. Addiction 106(3):631–638. doi:10.1111/j.1360-0443.2010.03226.x PubMedCrossRefGoogle Scholar
  10. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ et al (2008) Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services, Rockville, MDGoogle Scholar
  11. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Varenicline Phase 3 Study Group (2006) Varenicline, an alpha4-beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1):47–55PubMedCrossRefGoogle Scholar
  12. Heydari G, Talischi F, Tafti SF, Masjedi MR (2012) Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis 16(2):268–272. doi:10.5588/ijtld.11.0183 Google Scholar
  13. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Varenicline Phase 3 Study Group (2006) Efficacy of varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296(1):56–63PubMedCrossRefGoogle Scholar
  14. Kotz D, Fidler J, West R (2012) Very low rate and light smokers: smoking patterns and cessation-related behaviour in England, 2006–2011. Addiction 107(5):995–1002. doi:10.1111/j.1360-0443.2011.03739.x PubMedCrossRefGoogle Scholar
  15. Kotz D, Fidler JA, West R (2011) Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res 13(9):793–799. doi:10.1093/ntr/ntr075 PubMedCrossRefGoogle Scholar
  16. Lawrence D, Mitrou F, Zubrick SR (2011) Non-specific psychological distress, smoking status and smoking cessation: United States National Health Interview Survey 2005. BMC Publ Health 11:256. doi:10.1186/1471-2458-11-256 CrossRefGoogle Scholar
  17. Sicras Mainar A, Navarro Artieda R, Diaz Cerezo S, Marti Sanchez B, Sanz De Burgoa V (2011) Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care. Aten Primaria 43(9):482–489. doi:10.1016/j.aprim.2010.09.010 PubMedCrossRefGoogle Scholar
  18. Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, Sutherland G (2008) Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103(1):146–154PubMedCrossRefGoogle Scholar
  19. Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews(1)Google Scholar
  20. Steinberg MB, Bover MT, Richardson DL, Schmelzer AC, Williams JM, Foulds J (2011) Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. Drug Alcohol Depend 114(1):77–81. doi:10.1016/j.drugalcdep.2010.06.022 PubMedCrossRefGoogle Scholar
  21. Taggar J, Coleman T, Lewis S, Szatkowski L (2012) The impact of the quality and outcomes framework (QOF) on the recording of smoking targets in primary care medical records: cross-sectional analyses from The Health Improvement Network (THIN) database. BMC Publ Health 12(1):329CrossRefGoogle Scholar
  22. Tsukahara H, Noda K, Saku K (2010) A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J 74(4):771–778PubMedCrossRefGoogle Scholar
  23. Vangeli E, Stapleton J, Smit ES, Borland R, West R (2011) Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction 106(12):2110–2121. doi:10.1111/j.1360-0443.2011.03565.x PubMedCrossRefGoogle Scholar
  24. West R, Hajek P, Stead L, Stapleton J (2005) Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 100(3):299–303PubMedCrossRefGoogle Scholar
  25. West R, Zatonski W, Przewozniak K, Jarvis MJ (2007) Can we trust national smoking prevalence figures? Discrepancies between biochemically assessed and self-reported smoking rates in three countries. Cancer Epidemiol Biomark Prev 16(4):820–822CrossRefGoogle Scholar
  26. Wong SL, Shields M, Leatherdale S, Malaison E, Hammond D (2012) Assessment of validity of self-reported smoking status. Health Rep 23(1):47–53PubMedGoogle Scholar
  27. World Health Organization (WHO). (2011). WHO report on the global tobacco epidemic. Warning about the dangers of tobacco. GenevaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Cancer Research UK Health Behaviour Research CentreUniversity College LondonLondonUK
  2. 2.Department of General Practice, CAPHRI School for Public Health and Primary CareMaastricht University Medical CentreMaastrichtThe Netherlands

Personalised recommendations